Stocks
Axsome Therapeutics Financial Statements (AXSM) |
||||||||||
| Axsome Therapeuticssmart-lab.ru | % | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 06.11.2023 | 23.02.2024 | 06.05.2024 | 05.08.2024 | 12.11.2024 | 12.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 57.8 | 71.5 | 75.0 | 87.2 | 104.8 | 338.5 | |||
| Operating Income, bln rub | -62.1 | -98.1 | -68.7 | -78.0 | -62.6 | -307.5 | ||||
| EBITDA, bln rub | ? | -60.4 | -96.5 | -65.4 | -78.0 | -60.6 | -300.6 | |||
| Net profit, bln rub | ? | -62.2 | -98.7 | -68.4 | -79.3 | -64.6 | -311.0 | |||
| OCF, bln rub | ? | -53.5 | -30.4 | -53.5 | -30.1 | -18.6 | -132.6 | |||
| CAPEX, bln rub | ? | 0.371 | 0.007 | 0.098 | 0.052 | 0.150 | 0.307 | |||
| FCF, bln rub | ? | -53.9 | -30.4 | -53.6 | -30.2 | -18.5 | -132.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 113.4 | 168.3 | 135.6 | 157.2 | 158.9 | 620.0 | ||||
| Cost of production, bln rub | 6.53 | 7.38 | 8.13 | 8.06 | 8.44 | 32.0 | ||||
| R&D, bln rub | 28.8 | 30.8 | 36.6 | 49.9 | 45.4 | 162.6 | ||||
| Interest expenses, bln rub | 0.757 | 0.702 | 1.08 | 1.30 | 1.98 | 5.06 | ||||
| Assets, bln rub | 600.9 | 588.2 | 545.7 | 548.2 | 561.5 | 561.5 | ||||
| Net Assets, bln rub | ? | 269.5 | 191.0 | 144.0 | 102.9 | 92.9 | 92.9 | |||
| Debt, bln rub | 185.6 | 186.4 | 189.4 | 191.8 | 192.3 | 192.3 | ||||
| Cash, bln rub | 416.6 | 386.2 | 331.4 | 315.7 | 327.3 | 327.3 | ||||
| Net debt, bln rub | -231.0 | -199.8 | -142.0 | -123.9 | -135.0 | -135.0 | ||||
| Ordinary share price, rub | 69.9 | 79.6 | 79.8 | 80.5 | 89.9 | 64.4 | ||||
| Number of ordinary shares, mln | 47.1 | 47.3 | 47.4 | 47.6 | 48.1 | 48.1 | ||||
| Market cap, bln rub | 3 293 | 3 767 | 3 782 | 3 830 | 4 326 | 3 101 | ||||
| EV, bln rub | ? | 3 062 | 3 567 | 3 640 | 3 706 | 4 191 | 2 966 | |||
| Book value, bln rub | 203 | 126 | 80 | 41 | 32 | 32 | ||||
| EPS, rub | ? | -1.32 | -2.08 | -1.44 | -1.67 | -1.34 | -6.46 | |||
| FCF/share, rub | -1.14 | -0.64 | -1.13 | -0.63 | -0.38 | -2.75 | ||||
| BV/share, rub | 4.30 | 2.65 | 1.69 | 0.86 | 0.67 | 0.67 | ||||
| EBITDA margin, % | ? | -104.5% | -135.0% | -87.3% | -89.5% | -57.8% | -88.8% | |||
| Net margin, % | ? | -107.6% | -137.9% | -91.1% | -91.0% | -61.7% | -91.9% | |||
| FCF yield, % | ? | -4.34% | -3.87% | -5.11% | -4.39% | -3.06% | -4.28% | |||
| ROE, % | ? | -76.9% | -125.3% | -205.8% | -300.0% | -334.7% | -334.7% | |||
| ROA, % | ? | -34.5% | -40.7% | -54.3% | -56.3% | -55.4% | -55.4% | |||
| P/E | ? | -15.9 | -15.7 | -12.8 | -12.4 | -13.9 | -9.97 | |||
| P/FCF | -23.0 | -25.9 | -19.6 | -22.8 | -32.6 | -23.4 | ||||
| P/S | ? | 14.7 | 13.9 | 15.1 | 13.1 | 12.8 | 9.16 | |||
| P/BV | ? | 16.3 | 30.0 | 47.1 | 94.1 | 133.7 | 95.8 | |||
| EV/EBITDA | ? | -17.4 | -16.3 | -13.0 | -12.3 | -13.9 | -9.87 | |||
| Debt/EBITDA | 1.31 | 0.91 | 0.51 | 0.41 | 0.45 | 0.45 | ||||
| R&D/CAPEX, % | 7 754% | 440 043% | 37 335% | 95 871% | 30 259% | 52 975% | ||||
| CAPEX/Revenue, % | 0.64% | 0.01% | 0.13% | 0.06% | 0.14% | 0.09% | ||||
| Axsome Therapeutics shareholders | ||||||||||
